Meeting Banner
Abstract #1004

Residual Pituitary Adenomas After Surgical Treatment: Improved Depiction with Gadobenate Dimeglumine Compared to Gadopentetate Dimeglumine

Nicoletta Anzalone1, Paolo Vezzulli1, Elisa Scola1, Piero Picozzi1, Antonella Iadanza1, Miles A. Kirchin2

1Department of Neuroradiology, Ospedale San Raffaele, Milan, Italy; 2WorldWide Medical & Regulatory Affairs, Bracco Imaging SpA, Milan, Italy

Surgical debulking is often the first approach to management of patients with pituitary adenomas. However, residual adenomatous tissue after surgery is frequent and is associated with a high risk of tumor recurrence. Our intra-individual crossover comparison in 15 patients shows that improved depiction of residual tumor and better differentiation of tumor from adjacent normal structures is achievable on follow-up MRI with gadobenate dimeglumine at 0.1 mmol/kg bodyweight than with gadopentetate dimeglumine at the same dose. Improved tumor depiction allows more accurate definition of the surgical target volume for subsequent gamma knife therapy.